Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

Innovative Cellular Therapeutics

Status

Unknown

Conditions

Lymphoma, B-Cell

Leukemia, B-Cell

Treatments

Biological: CD19CART

Study type

Interventional

Funder types

Other

Identifiers

NCT02813837

SCT019-01

Details and patient eligibility

About

Full description

This single arm, open-label, multi-center clinical trial is studying CD19 targeted chimeric antigen receptor T cells therapy in treating patients with CD19 positive malignant B-cell derived leukemia and lymphoma that is relapsed (after stem cell transplantation or chemotherapy) or refractory to chemotherapy. When patients enroll in this trial, autologous CD19CART cells were generated from the mononuclear cells of the patient's peripheral blood (PB). During the term of cell preparation of CD19CART cells, patients will receive a conditioning regimen. One day after completing conditioning regimen, the patient will be given infusions of CD19CART cells into the vein over a period of 1 to 3 days. Patients will be monitored for a response, toxic effects, and the expansion and persistence of circulating CD19CART cells.

Enrollment

30 estimated patients

Sex

All

Ages

Under 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients diagnosed as CD19 positive refractory and relapsed B cell hematologic malignancies included acute lymphoblastic leukemia (ALL),chronic lymphocytic leukemia(CLL),non-Hodgkin's lymphoma(NHL)
not eligible or appropriate for auto-HSCT or allo-HSCT or relapsed after hematopoietic stem cell transplant(HSCT)
At least one measurable lesion defined as one lesion larger than 1.5cm or two lesion more than 1.0cm(for patients with NHL )
Age ≤60 years
Eastern Cooperative Oncology Group(ECOG) Performance status 0 to 2, Expected survival > 6 months
Left Ventricular Ejection Fraction (LVEF) > 50%
no history of other malignancies;
no other serious diseases which conflict with the treatment in the present trial
All patients should consent to adopt efficient contraception methods during the treatment and after the treatment. The pregnant tests of women who are in child bearing period should be negative before the treatment.
patients should understand and are willing to participate in the trial. Inform consent form is supposed to obtained before treatment

Exclusion criteria

Diagnosis or classification undefined
Those with primary central nervous system lymphoma or testicular leukaemia or lymphoma
Patients with a known history or prior diagnosis of epilepsia or other disease affecting the central nervous system, or serious mental diseases;
Patients who have secondary leukaemia or lymphoma after chemotherapy or radiotherapy for other malignancies
Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy, concurrent use of immunosuppressant medications
Class III/IV cardiovascular disability according to the New York Heart Association Classification
Pregnant or lactating women(the safety of this therapy on unborn children is not known)
With active infection
Active hepatitis B, hepatitis C or syphilis infection
Patients use of systemic steroids within 2 weeks. Recent or current use of inhaled steroids is not exclusionary
Prior treatment with gene therapy product
Cluster of differentiation 3(CD3) positive cells<0.9x10^4/ml in peripheral blood (PB)
Organ function meeting following criteria: liver and renal function: alanine aminotransferase(ALT)/aspartate aminotransferase(AST) > 3 times the upper limit of normal, or bilirubin>2.0 mg/dl（34.2umol/L）, or creatinine >2.5mg/dl（221.0umol/L） ; hematopoietic function:Neutrophil count<1.0x10^9/L，hemoglobin<80g/L，platelet <50x10^9/L(for patients with NHL )
Any uncontrolled active medical disorder that would preclude participation as outlined
HIV infection
The researchers considered unsuitable to participate in this clinical study.
Patients with poor compliance